A series of 3,6-disubstituted [1, 2, 4] triazolo [3,4-b][1,3,4]thiadiazoles 5a -l bearing an adamantyl moiety were synthesized by condensation of 4-amino-5-aryl-2H-1,2,4-triazole-3(4H)-thiones 4a -l with adamantyl-1-carboxylic acid in the presence of POCl 3 . The structures of the newly synthesized compounds were established using spectroanalytical techniques and verified further by the crystal structure determination of compounds 5a and 5j. The compounds were screened for their antiproliferative activity against a large panel of human cell lines.
Introduction
Fused heterocycles have received significant attention due to their synthetic and biological importance, and 1,2,4-triazole-3-thiones/thiols are excellent candidates for their synthesis. A number of significant activities, like antitumor and antimicrobial, have been associated with these condensed heterocycles [1 -6] . Moreover, among various substituents, adamantyl derivatives are gaining importance in well known drugs like Rimantadine, Memantine, Adapalene, Adatanserine and others in clinical trials [7, 8] . The adamantyl derivatives are also recognized for their activity against influenza [9] and HI viruses [10] . Some other adamantyl derivatives have been used as anti-inflammatory [11, 12] , antimicrobial [13, 14] , antimalarial [15] , and antidepressant agents [16] as well as inhibitors of 11β -hydroxysteroid dehydrogenase type 1 (11β -HSD1) [17] .
In continuation of our work on the synthesis and biological evaluation of five-membered heterocycles [18a -f], we have synthesized triazolothiadiazoles bearing an adamantyl moiety and evaluated their antiproliferative activities against a large panel of human cell lines.
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Results and Discussion

Synthesis
The synthesis of the adamantyl-bearing 3,6-disubstituted [1, 2, 4] triazolo [3,4-b] [1,3,4]thiadiazoles 5a -l was carried out by treatment of 4-amino-5-aryl-2H-1,2,4-triazole-3(4H)-thiones 4a -l with adamantyl-1-carboxylic acid [6] . 4-Amino-5-aryl-2H-1,2,4-triazole-3(4H)-thiones were prepared from aryl hydrazides 3a -l by reaction with CS 2 in the presence of KOH, followed by cyclization with hydrazine hydrate [18a]. The aryl hydrazides 3a -l were synthesized from the corresponding aryl benzoic acids 1a -l via esterification to 2a -l, by following a reported procedure [18f]. The synthetic steps are illustrated in Scheme 1.
The condensation of 4a -l with adamantyl-1-carboxylic acid to 5a -l was achieved in 64 -84 % yield. The structures of 5a -l were confirmed by 1 Hand 13 C-NMR, IR and mass spectra. The cyclization of 4a -l to [1, 2, 4] triazolo [3,4-b] [1, 3, 4] thiadiazoles 5a -l was followed by the IR and 1 H-NMR spectra, where the NH/NH 2 signals disappeared in comparison to triazolethiones 4a -l. In the 1 H-NMR spectra of 5a -l, the adamantane protons resonated in the region δ = Scheme 1. Synthesis of 3,6-disubstituted [1, 2, 4] triazolo [3,4-b] [1, 3, 4] thiadiazoles.
1.85 -2.21 ppm as multiplets. Four aromatic protons exhibited multiplicities depending on the position of the substituent on the benzene ring. In addition, the aromatic proton signals in 5d -f exhibited splittings due to proton-fluorine coupling. In the 13 C-NMR spectra, adamantyl carbons appeared in the region δ = 21.2 -28.5 ppm, whereas the signals in the aromatic region of δ = 123.0 -140.0 ppm varied from four to six due to different substitution patterns on the aryl ring. The doublets at δ = 159.9, 162.8 and 163.8 ppm with large J C,F values (254.2, 244.5, and 249.0 Hz) were assigned to C-2, C-3 and C-4 of the aromatic residues in compounds 5d, 5e, and 5f, respectively. The signal of C-8 of the triazolothiadiazole unit was observed in the region δ = 142.9 -149.9 ppm, whereas C-3-triazole resonated in the region of 153.2 -154.8 ppm. The higher-field signals between δ = 179.4 and 182.3 ppm were assigned to C-6-S.
The constitution of compounds 5a -l was further confirmed by the single crystal X-ray studies of compounds 5a and 5j ( Figs. 1 and 2 ). Compound 5j crystallizes with four independent molecules in the asymmetric unit, all of which differ in molecular conformation. S-C2-C10-C (−14.6 • for 5a, −27.6, 42.7, −28.1, 14.9 • for 5j, all involving C11 as the fourth atom).
In vitro antiproliferative activity
Compounds 5a -l were tested in vitro against a large panel of human cell lines derived from hematological CD4 + human T cells containing an integrated HTLV-1 genome (MT-4), CD4 + human acute T-lymphoblastic leukaemia (CCRF-CEM), human splenic B-lymphoblastoid cells (WIL-2NS), human acute B-lymphoblastic leukemia (CCRF-SB) and solid skin melanoma (SK-28), breast adenocarcinoma (MCF-7), lung squamous carcinoma (SK-MES-1), hepatocellular carcinoma (HepG-2), prostate carcinoma (DU-145) or normal tissues [lung fibroblasts (MRC-5)]. The Microculture Tetrazolium Assay (MTT) method [19] was used for estimation of the in vitro tumor-inhibiting activity of the tested Fig. 2 . Structure of compound 5j (four independent molecules) in the crystal. Displacement ellipsoids at the 50 % probability level.
compounds. The cell lines of tumor subpanels were incubated within five concentrations (0.01 -100 g mL −1 ) of each test compound for 48 h. For comparative purposes, we evaluated the cytotoxic activities of the compounds relative to Doxorubicin. All compounds were inactive except 5a and 5d which showed activity against human CD4 + T cells containing an integrated HTLV-1 genome (CD + ) (CC 50 = 45 µ M and 47 µ M, respectively) and human acute T-lymphoblastic leukemia (CCRF-CEM) cell lines (CC 50 = 40 µ M, for both compounds). Furthermore, compounds 5a and 5d exhibited activity against human acute B-lymphoblastic leukaemia (CCRF-SB) lines (CC 50 = 50 µ M and 48 µ M, respectively) and human splenic lymphoblastoid (WIL-2NS) lines (CC 50 = 52 µ M and 44 µ M, respectively).
Conclusion
A series of 3,6-disubstituted [1, 2, 4] triazolo [3,4-b] [1, 3, 4] thiadiazoles 5a -l were synthesized and characterized by spectral techniques. The structures of 5a and 5j were further confirmed by single crystal X-ray diffraction studies. Compounds 5a and 5d exhibited antiproliferative activity against some selected human cell lines. Introduction of methyl or fluoro residues in the ortho position of the aromatic ring of 5 generally enhanced the potency: dramatic changes in activity were observed with the other congeners (compounds 5b, c, 5e -l). Thus, substitution of the aromatic ring by chloro or bromo residues at ortho, meta or para positions (5g -l) did not show any activity. Similary, 3-or 4-methylphenyl (5b, c), or 3-or 4-fluorophenyl groups (5e, f) exhibited no activity as well.
Experimental Section
General
Melting points were measured using a Stuart SMP3 melting point apparatus and are uncorrected. The R f values were determined using pre-coated silica gel aluminium plates with silica gel 60 F 254 (Merck, Germany). Column chromatography was carried out using silica gel 60 (0.063 -0.200 mm) obtained from Merck, Germany. The IR spectra were recorded on an FTS 3000 MX, Bio-Rad Merlin spectrometer (Excalibur Model). 1 H-and 13 C-NMR spectra were recorded on a Bruker Avance 300 MHz-NMR spectrometer and signals calibrated to the residual signals of the solvent. The EI mass spectra were carried out using an Agilent Technologies 6890N (GC) mass spectrometer and an inert selective detector 5973. 4-Amino-5-aryl-2H-1,2,4-triazole-3(4H)-thiones 4a -l were prepared according to a reported procedure [19] .
General procedure for the synthesis of 3,6-disubstituted [1, 2, 4] triazolo [3,4-b] [1, 3, 4] 
thiadiazoles (5a -l)
A mixture of the respective triazolethione 4a -l (0.90 mmol) and adamantane-1-carboxylic acid (0.90 mmol) was heated under reflux for 4 h in the presence of POCl 3 (5.0 mL). The reaction mixture was cooled to r. t., poured on ice and neutralized with solid K 2 CO 3 until pH = 8. The precipitated solid was filtered, washed with excess of water and purified by column chromatography (n-hexane : ethyl acetate 7 : 3). [1, 2, 4] triazolo [3,4-b] [1, 3, 4] [1, 2, 4] triazolo [3,4-b] [1, 3, 4] [1, 2, 4] triazolo [3,4-b] [1, 3, 4] Adamantyl)-3-(3-fluorophenyl) - [1, 2, 4] triazolo [3,4-b] [1, 3, 4] [1, 2, 4] triazolo [3,4-b] [1, 3, 4] [1, 2, 4] triazolo [3,4-b] [1, 3, 4] [1, 2, 4] triazolo [3,4-b] [1, 3, 4] 
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